Nanox Aims to Reshape European Radiology with AI and Accessible 3D Imaging

PETACH TIKVA, Israel – February 17, 2026 – NANO-X IMAGING LTD is poised to make a significant push into the European healthcare market, announcing it will conduct the first-ever live demonstrations of its Nanox.ARC medical imaging system on the continent at the upcoming European Congress of Radiology (ECR) 2026 in Vienna. The Israeli innovator will also showcase a suite of artificial intelligence solutions designed to transform routine CT scans into powerful tools for the early detection of chronic diseases, signaling a strategic effort to disrupt the traditional imaging landscape with a focus on affordability, accessibility, and preventive care.

The move is a critical test for the Nasdaq-listed company (NNOX), which aims to carve out a niche in a market dominated by established giants like Siemens Healthineers and Philips. By combining a novel imaging device with a powerful AI and cloud platform, Nanox is betting that European healthcare systems are ready for a new model of delivering advanced diagnostics.

A New Era for Accessible Imaging?

At the heart of Nanox’s strategy is the Nanox.ARC, a CE-marked and FDA-cleared digital tomosynthesis system. Unlike conventional CT scanners, the ARC is designed with a smaller footprint, simplified installation requirements, and a significantly lower radiation dose. The company claims these features, combined with a lower cost structure, make 3D imaging viable in a wider range of settings, from community clinics and outpatient centers to resource-constrained hospitals that cannot accommodate or afford traditional CT equipment.

This approach directly targets a growing trend in European healthcare: the decentralization of services to improve patient access, reduce wait times, and control costs. The ability to deploy advanced imaging outside of major urban medical centers could be a game-changer for early diagnosis, particularly in rural and underserved communities.

“European healthcare systems need advanced imaging solutions that can operate beyond major medical centers, and that is exactly what the Nanox.ARC was designed to do,” said Erez Meltzer, CEO and Acting Chairman of Nanox, in a statement. The company's presence at ECR, a year after receiving its European CE Mark certification, represents a major milestone in its expansion plans. At the Vienna congress, Nanox will not only feature live demonstrations of the system every 30 minutes but also present clinical data on its potential role in lung cancer screening.

Turning Routine Scans into Lifesaving Early Warnings

Beyond the hardware, Nanox is heavily promoting its AI-driven platform, which aims to unlock "latent data" hidden within millions of routine CT scans performed annually. The company will showcase its FDA-cleared and CE-marked AI solutions that automatically analyze these scans for early indicators of some of the most prevalent chronic conditions.

These tools include the AI Cardiac solution (HealthCCSng) for detecting coronary artery calcification, a key predictor of heart disease; the AI Bone solution (HealthOST) for identifying vertebral compression fractures and low bone density indicative of osteoporosis; and the AI Liver solution (HealthFLD) for spotting signs of fatty liver disease. This strategy aligns with a major shift in medicine toward proactive, preventive health, leveraging AI to flag at-risk patients long before symptoms appear.

The potential impact of such technology is substantial. Independent research has shown that AI algorithms can predict the risk of a heart attack from a routine cardiac CT scan up to ten years in advance with greater accuracy than traditional risk scores. In lung cancer screening, AI models have demonstrated over 90% sensitivity, helping to reduce false positives and radiologists' workload. Nanox will also present two new AI solutions currently under development, one for aortic valve calcification and another for body composition measurement, further broadening the scope of its opportunistic screening platform.

A Disruptive Strategy Meets a Competitive Market

Nanox’s vision extends beyond selling individual products. The company is promoting an integrated, end-to-end platform that includes the Nanox.ARC hardware, Nanox.AI software, a cloud platform for data management, and teleradiology services. Central to this is a proposed pay-per-scan business model, which aims to lower the significant upfront capital investment typically required for advanced imaging equipment. This "as-a-service" approach could make its technology more attractive to providers with limited budgets.

However, the path to widespread adoption in Europe is complex. The continent's diverse healthcare systems feature a patchwork of reimbursement models, and any new technology must prove its cost-effectiveness to gain traction. Furthermore, strict data privacy regulations like GDPR present a high bar for cloud-based health platforms.

Nanox also faces formidable competition. ECR 2026 will feature industry titans like Siemens Healthineers, which is heavily focused on its own AI-driven solutions for cancer care and sustainable radiology. These established players have deep relationships with European health systems and vast service networks.

Investors are watching closely. Nanox has set an ambitious 2026 revenue outlook of $35 million, far exceeding analyst expectations and causing a recent surge in its stock price. While Wall Street analysts maintain a largely bullish "Buy" rating, citing the company's disruptive potential, some "bears" point to a significant cash burn rate and past stock volatility as signs of high risk. The company's performance at ECR and its ability to convert interest into tangible commercial partnerships will be crucial to justifying its high valuation and sustaining investor confidence.

Spotlight on ECR 2026: Putting Claims to the Test

The European Congress of Radiology, with its theme "The Art of AI in Clinical Practice," provides the perfect stage for Nanox to make its case. The company's agenda is packed with scientific presentations designed to back its technological claims with clinical evidence.

Dr. Nogah Shabshin, Medical Director of Nanox's ARC Division, will deliver an oral presentation on the role of digital tomosynthesis in making lung cancer screening more efficient at lower radiation doses. Meanwhile, Chief Medical Officer Dr. Orit Wimpfheimer will present on how Nanox AI activates latent data from CT scans for early disease detection. Several poster presentations will feature new data from the ADOPT study conducted in UK hospitals, highlighting the real-world impact of its AI-enabled vertebral fracture identification on clinical workflows.

By engaging directly with thousands of radiologists, hospital administrators, and researchers, Nanox is seeking to build the clinical credibility and market momentum needed for its European offensive. The congress will serve as a critical barometer of whether the company’s vision for a more accessible and preventive future for medical imaging can resonate with the gatekeepers of European healthcare.